Evidence map›Paper›PMID 31050820›Full record

ArticleInternational journal of cancer2019

Transcriptomic profiling reveals three molecular phenotypes of adenocarcinoma at the gastroesophageal junction.

Jan Bornschein, Lorenz Wernisch, Maria Secrier, Ahmad Miremadi, Juliane Perner, Shona MacRae, Maria O'Donovan, Richard Newton, Suraj Menon, Lawrence Bower and 10 more

Abstract read
In one paragraph

Article in International journal of cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Jan BornscheinMRC Cancer Unit, Hutchison/MRC Research Centre, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0001-8673-3122
Lorenz WernischMRC Biostatistics Unit, University of Cambridge, Cambridge, United Kingdom.
Maria SecrierCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
Ahmad MiremadiDepartment of Histopathology, Addenbrooke's Hospital, Cambridge University Hospitals, Cambridge, United Kingdom.
Juliane PernerCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
Shona MacRaeMRC Cancer Unit, Hutchison/MRC Research Centre, University of Cambridge, Cambridge, United Kingdom.
Maria O'DonovanDepartment of Histopathology, Addenbrooke's Hospital, Cambridge University Hospitals, Cambridge, United Kingdom.
Richard NewtonMRC Biostatistics Unit, University of Cambridge, Cambridge, United Kingdom.
Suraj MenonCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
Lawrence BowerCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
Matthew D EldridgeCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
Ginny DevonshireCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
Calvin CheahMRC Cancer Unit, Hutchison/MRC Research Centre, University of Cambridge, Cambridge, United Kingdom.
Richard TurkingtonDepartment of Oncology, Queen's University, Northern Ireland, United Kingdom.
Richard H HardwickDepartment of Surgery, Addenbrooke's Hospital, Cambridge University Hospitals, Cambridge, United Kingdom.
Michael SelgradDepartment of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University, Magdeburg, Germany.
Marino VeneritoDepartment of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University, Magdeburg, Germany.
Peter MalfertheinerDepartment of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University, Magdeburg, Germany.
OCCAMS Consortium
Rebecca C FitzgeraldMRC Cancer Unit, Hutchison/MRC Research Centre, University of Cambridge, Cambridge, United Kingdom.

Funding

Biotechnology and Biological Sciences Research Council BB/N018176/1Cancer Research UK 16463Cancer Research UK 20406Cancer Research UK 22131Cancer Research UK 22720Cancer Research UK 23924Cancer Research UK 25487Cancer Research UK RG66287Department of Health RG67258European Research Council 609822Medical Research Council MC_UU_00002/1Medical Research Council MC_UU_12022/2Swiss National Science Foundation 166608
6 · The paper itself

Abstract

Cancers occurring at the gastroesophageal junction (GEJ) are classified as predominantly esophageal or gastric, which is often difficult to decipher. We hypothesized that the transcriptomic profile might reveal molecular subgroups which could help to define the tumor origin and behavior beyond anatomical location. The gene expression profiles of 107 treatment-naïve, intestinal type, gastroesophageal adenocarcinomas were assessed by the Illumina-HTv4.0 beadchip. Differential gene expression (limma), unsupervised subgroup assignment (mclust) and pathway analysis (gage) were undertaken in R statistical computing and results were related to demographic and clinical parameters. Unsupervised assignment of the gene expression profiles revealed three distinct molecular subgroups, which were not associated with anatomical location, tumor stage or grade (p > 0.05). Group 1 was enriched for pathways involved in cell turnover, Group 2 was enriched for metabolic processes and Group 3 for immune-response pathways. Patients in group 1 showed the worst overall survival (p = 0.019). Key genes for the three subtypes were confirmed by immunohistochemistry. The newly defined intrinsic subtypes were analyzed in four independent datasets of gastric and esophageal adenocarcinomas with transcriptomic data available (RNAseq data: OCCAMS cohort, n = 158; gene expression arrays: Belfast, n = 63; Singapore, n = 191; Asian Cancer Research Group, n = 300). The subgroups were represented in the independent cohorts and pooled analysis confirmed the prognostic effect of the new subtypes. In conclusion, adenocarcinomas at the GEJ comprise three distinct molecular phenotypes which do not reflect anatomical location but rather inform our understanding of the key pathways expressed.

Indexed as

AdenocarcinomaEsophageal NeoplasmsEsophagogastric JunctionGene Expression ProfilingHumansImmunohistochemistryPhenotypePrognosisProspective StudiesStomach NeoplasmsTranscriptomeesophageal adenocarcinomagastric cancergastroesophageal junctiongene expression profilingSiewert classification

Identifiers

PMID31050820
PMCPMC6851674

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.